Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

• Main Authors: Maria Stella (Author), Maria Giuliani (Author), Alessia Biolchi (Author), Sara Tomei (Author), Rosita De Paola (Author), Xilian Bai (Author), Ray Borrow (Author), Jay Lucidarme (Author), Rita La Gaetana (Author), Daniela Toneatto (Author), Mariagrazia Pizza (Author), Laura Serino (Author), Elena Mori (Author), Marzia Monica Giuliani (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup...